Navigation Links
Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
Date:10/27/2008

NANJING, China, Oct. 27 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today its participation in the Goldman Sachs China Investment Frontier Conference 2008. The conference will be held at the Grand Hyatt Beijing hotel on November 3-4, 2008.

Simcere's chief executive officer, Jinsheng Ren, chief financial officer, Frank Zhigang Zhao, and vice president of marketing, Mark Chen, will attend the conference on Thursday November 4. Jinsheng Ren will speak at the Track I Panel session headlined Healthcare: Reform of the Healthcare System: Impact and Likely Winners, which will take place on November 4, between 08:00-09:00 Beijing time. Later that afternoon, Frank Zhigang Zhao will give a company presentation to investors between 16:30-17:30.

A copy of Simcere's investor presentation will be available on the investor relations portion of the Company's Web site, located at http://www.simcere.com .

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti- stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 39 principal pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

For investor and media inquiries, please contact:

In Nanjing:

Frank Zhigang Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556-6666 ext. 8818

Email: ir@simcere.com

In Beijing:

Kejia Wu

Brunswick Group

Tel: +86-10-6566-4651

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852-3512-5033

In New York:

Michael Guerin

Brunswick Group LLC

Tel: +1-212-333-3810


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
3. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
4. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
7. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
8. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
9. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
10. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... KS (PRWEB) , ... January 24, 2017 , ... ... Premensa, a leading natural supplement for relieving premenstrual syndrome, or PMS . ... at some point. These symptoms can include cramps, constipation, irritability, headaches, fatigue, and ...
(Date:1/24/2017)... ... January 24, 2017 , ... “Mysteries Revealed On Speaking In Tongues”: ... is available to all Christians. “Mysteries Revealed On Speaking In Tongues” is the creation ... a Christian-based talk show located in Michigan. , “We need to partner with ...
(Date:1/24/2017)... ... January 23, 2017 , ... The Pharmacy and Medically Underserved ... bipartisan original co-sponsorship of nearly one-quarter of the U.S. House of Representatives. The ... Chain Drug Stores (NACDS) strongly backs the legislation. , “NACDS thanks for their ...
(Date:1/24/2017)... ... January 23, 2017 , ... The ... Buzzies users who entered metrics into the product’s app. The data replicates ... data showed that within just 30 seconds of using Buzzies, people experienced a ...
(Date:1/23/2017)... ... 23, 2017 , ... PKF O’Connor Davies , LLP, the nation’s 26th ... at the Firm, will participate in the 40th Annual "Empire State Building Run Up" ... up 1,576 steps, a vertical distance equal to about a fifth of a mile, ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Jan. 23, 2017 LifeVac, the revolutionary device ... airway and prevented choking deaths, welcomes Steve Way ... the LifeVac team as Official Spokesperson. ... LifeVac team," said Arthur Lih , Founder and ... LifeVac and his mission to raise awareness about the ...
(Date:1/23/2017)... 23, 2017 Research and Markets has announced the ... - Product - Forecast to 2025" report to their offering. ... Report Highlights: ... trends to identify the investment opportunities Market forecasts till ... Key market trends across the business segments, Regions and Countries ...
(Date:1/23/2017)... January 23, 2017 Stock-Callers.com today presents ... (NASDAQ: CPRX ), Sophiris Bio Inc. (NASDAQ: ... ), and Agile Therapeutics Inc. (NASDAQ: AGRX ). ... somewhat lower in late trade on Friday, January 20 th ... 0.3%, while shares of health care companies in the S&P ...
Breaking Medicine Technology: